Dr. Fan is a lead oncology medical officer with 17 years of experience at the Center of Biologics Evaluation and Research (CBER) and the Center of Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA). Dr. Fan serves as a team leader at the oncology branch and as an acting branch chief at the Malignant Hematology Branch at the Office of Tissues and Advanced Therapies (OTAT), CBER. OTAT facilitates the development and approval of the most innovative cancer therapeutics with curative potential. These therapeutics include chimeric antigen receptor (CAR) T cells, adoptive T cell therapies, tumor neoantigen-based personalized immunotherapies, oncolytic viruses, and combinations of cellular and gene therapies with other immunologic agents such as checkpoint inhibitors. Dr. Fan is a medical oncologist certified by the American Board of Internal Medicine (ABIM). She received an M.D. from Zunyi Medical College, and a M.Sc. in medical genetics from Hunan Medical University, China. She also holds a Ph.D. in medical genetics from Umea University in Sweden. Prior to joining the FDA, Dr. Fan conducted post-doctoral research in gene mapping and cloning for neurogenetic disorders, including Amyotrophic Lateral Sclerosis (ALS), at Northwestern University in Chicago, USA. Her regulatory expertise focuses on clinical trial design and development of gene and cellular therapies and precision medicine in oncology.
